Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vericiguat oral suspension (Formulation 4)
- Development stage
- Approved
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vericiguat oral suspension (Formulation 4) is a specific pediatric liquid formulation of vericiguat (BAY 1021189) developed by Bayer. This particular formulation is characterized by increased levels of sucralose and flavoring agents compared to other test versions, designed to optimize palatability for children. Vericiguat is a small molecule stimulator of soluble guanylate cyclase (sGC), an enzyme in the nitric oxide (NO) signaling pathway. It works by directly stimulating sGC independently of NO and sensitizing the enzyme to endogenous NO, thereby increasing levels of cyclic guanosine monophosphate (cGMP). Elevated cGMP leads to smooth muscle relaxation and vasodilation, which helps improve cardiac function and reduce myocardial stiffness. While vericiguat is approved in tablet form (Verquvo) for adults with symptomatic chronic heart failure and reduced ejection fraction (HFrEF), this oral suspension is being evaluated for use in pediatric heart failure patients.
- Brand names
- Verquvo
- Other names
- Formulation 4Formulation4Formulation-4Vericiguat pediatric oral suspension
02
Targets
GUCY2D (Guanylate cyclase 2D)GUCY1B1 (Guanylate cyclase soluble subunit beta-1)sGC (Soluble Guanylyl Cyclase)
Beyond the preview
Go deeper on Vericiguat oral suspension (Formulation 4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vericiguat oral suspension (Formulation 4).